Literature DB >> 9605086

Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass.

K N Maquelin1, R J Berckmans, R Nieuwland, M C Schaap, K ten Have, L Eijsman, A Sturk.   

Abstract

OBJECTIVES: Several investigators have reported decreased expression of glycoprotein Ib on the platelet surface during coronary artery bypass grafting, but others could not confirm this finding. Because platelet glycoprotein Ib functions as an adhesion receptor for von Willebrand factor and other adhesive proteins, this decreased expression may explain excessive postoperative blood loss. In this study the expressions of glycoprotein Ib and other platelet activation markers were studied in the systemic and pericardial blood of seven patients undergoing coronary artery bypass grafting. Pericardial blood was recently shown to have high activation levels of fibrinolytic and coagulation pathways; we hypothesized that this local blood activation might be paralleled by extensive platelet activation and associated disappearance of glycoprotein Ib.
METHODS: Expression of platelet surface antigens was determined by whole-blood double-label flow cytometry.
RESULTS: Glycoprotein Ib expression in systemic blood decreased 10% (p = 0.03) from preoperative levels at the start of cardiopulmonary bypass and 30% (p = 0.04) before release of the aortic crossclamp. Expression in pericardial blood at these times decreased by 50% and 51%, respectively (p = 0.003, p = 0.009). No changes were observed in the expression of the platelet activation antigens CD62P (P-selectin, indicating platelet alpha-granular release) and CD63 (indicating lysosomal release) or in binding of monoclonal antibody PAC-1 (detecting the fibrinogen-binding receptor conformation of the glycoprotein IIb-IIIa complex).
CONCLUSION: Glycoprotein Ib disappeared from the platelet surface during bypass grafting, most notably in pericardial blood. No increased expression of CD62P, CD63, or PAC-1 was found, indicating the absence of general platelet activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605086     DOI: 10.1016/s0022-5223(98)70416-7

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.

Authors:  J Graff; D Andries; M Elsner; D Westrup; S Bassus; N Franz; U Klinkhardt; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

2.  Thrombocytopenia After Cardiopulmonary Bypass Is Associated With Increased Morbidity and Mortality.

Authors:  Benjamin R Griffin; Michael Bronsert; T Brett Reece; Jay D Pal; Joseph C Cleveland; David A Fullerton; Katja M Gist; Anna Jovanovich; Diana Jalal; Sarah Faubel; Muhammad Aftab
Journal:  Ann Thorac Surg       Date:  2019-12-06       Impact factor: 4.330

3.  Abnormal whole blood thrombi in humans with inherited platelet receptor defects.

Authors:  Francis J Castellino; Zhong Liang; Patrick K Davis; Rashna D Balsara; Harsha Musunuru; Deborah L Donahue; Denise L Smith; Mayra J Sandoval-Cooper; Victoria A Ploplis; Mark Walsh
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.